报价延迟最少15分钟:2026/07/10 20:17 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.08 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.51/-0.31
|
|
企业价值
158.30M
|
| 资产负债 |
|
每股账面净值
-0.33
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
4.06M
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA. |
